Ratio disruption of the Δ133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1181-1188

  Nutthasirikul, Nichapavee ^a,b   Limpaiboon, Temduang ^a,b   Leelayuwat, Chanvit ^a,b   Patrakitkomjorn, Siriporn ^a,b   Jearanaikoon, Patcharee ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Biomarker; Cholangiocarcinoma; Isoform; Liver fluke; P53 family; Poor prognosis

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN P53;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER SURVIVAL; FEMALE; HUMAN; MALE; MUTANT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; CHOLANGIOCARCINOMA; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84874587000     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1818     Document Type: Article

References (21)

1. Sripa B and Pairojkul C: Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 24:349-356, 2008.
2. Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308-321, 2008.
3. Stiewe T: The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7:165-168, 2007.
4. Murray-Zmijewski F, Lane DP and Bourdon JC: p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13:962-972, 2006.
5. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A: p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713, 1999.
6. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer 97:277-282, 2007.
7. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al: p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137, 2005.
8. Marcel V, Perrier S, Aoubala M, et al: Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett 584:4463-4468, 2010.
9. Helton ES, Zhu J and Chen X: The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 281:2533-2542, 2006.
10. Marchini S, Marabese M, Marrazzo E, et al: DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 19:501-507, 2008.
11. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW and Ngan HY: Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12:3922-3927, 2006.
12. Marabese M, Marchini S, Marrazzo E, et al: Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 44:131-141, 2008.
13. Müller M, Schilling T, Sayan AE, et al: TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12:1564-1577, 2005.
14. Soldevilla B, Díaz R, Silva J, et al: Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res 17:6029-6039, 2011.
15. Limpaiboon T, Sripa B, Wongkham S, Bhudhisawasdi V, Chau-in S and Teerajetgul Y: Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepatogastroenterology 51:25-28, 2004.
16. Yang B, House MG, Guo M, Herman JG and Clark DP: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 18:412-420, 2005.
17. Lin Z, Nan Y, Zhang X, Zhao Y, Kim C and Kim I: Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. Int J Gynecol Cancer 16:1643-1647, 2006.
18. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W and Nakanuma Y: Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 35:230-240, 1999.
19. Song W, Huo SW, Lü JJ, et al: Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl) 122:921-926, 2009.
20. Fujita K, Mondal AM, Horikawa I, et al: p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11:1135-1142, 2009.
21. Conforti F, Yang AL, Agostini M, et al: Relative expression of TAp73 and ΔNp73 isoforms. Aging (Albany, NY) 4:202-205, 2012.